Understanding ICH Q3C: Residual Solvents in APIs Explained

The International Council for Harmonisation (ICH) provides clear guidelines for the solvents’ impurities in Active Pharmaceutical Ingredients (APIs). In this context, ICH Q3C guidelines are useful in regulatory submissions. This blog explains the features of the ICH Q3C guidelines. Specifically, we will learn about the solvent classes, control strategies, analytical approaches, reporting methods, and regulatory expectations for residual solvents in APIs.

Table of contents

1. Introduction
2. Why residual solvents matter
3. Scope of ICH Q3C
4. Solvent classification and limits
5. Analytical approaches and reporting
6. Control strategies in process development
7. Critical discussion—gaps and practical issues
8. Practical checklist for chemistry graduates
9. References

Introduction

In addition to the process-related impurities and degradation impurities, the residual solvents remain one of the most closely examined impurity categories in APIs. They originate from organic solvents used during synthesis, purification, crystallization, and drying. Although most solvents are removed during processing, their trace levels often persist in the final API. These residues can pose toxicological risks, affect product stability, and trigger regulatory concerns if not properly controlled.

Therefore, this challenge is resolved by ICH Q3C, the global guideline that defines acceptable limits for residual solvents in pharmaceuticals. ICH Q3C establishes a framework that is based on toxicological evaluation and Permitted Daily Exposure (PDE). Also, it classifies solvents by risk and sets concentration limits aligned with patient safety.

Why residual solvents matter

The presence of solvent impurities matters because of the following reasons:

• Residual solvents are volatile organic chemicals left after synthesis or formulation.
• They can affect patient safety and product quality. (European Medicines Agency (EMA))
• Regulators expect control and justification. (U.S. Food and Drug Administration)

Scope of ICH Q3C

The scope of the ICH Q3C guidelines includes identification of the possible solvent impurities in APIs. Also, it focuses on the maximum concentration limits of the residual solvent impurities.

• ICH Q3C defines residual solvents as organic volatile chemicals used or produced in the manufacturing process of the API.
• It gives toxicologically-based limits (PDEs) and concentration limits. (ICH Database)
• The guideline is harmonized across major authorities (ICH, FDA, EMA) to ensure uniformity

Solvent classes and limits

ICH divides solvents into three classes based on toxicity and recommended action:

1. Class 1—Solvents to avoid
   • These solvents are known human carcinogens or strongly environmentally hazardous.
   • Example: Benzene. Avoid using them in synthesis if possible.
2. Class 2—Solvents to be limited
   • These have inherent toxicity. The solvent limits are set by permitted daily exposure (PDE) and converted to concentration (ppm) for the drug product.
   • Examples: Methylene chloride and toluene.
   • Methylene chloride has a Permitted Daily Exposure (PDE) of 6.0 mg/day, and the permissible concentration limit is $$600 ppm.
   • Similarly, toluene has a Permitted Daily Exposure (PDE) of 8.9 mg/day, and the permissible concentration limit is $$890 ppm.
3. Class 3—Solvents with low toxic potential
   • These solvents have low toxic potential and are less restricted.
   • Examples: ethanol, acetone. If only Class 3 solvents are present, non-specific methods (e.g., loss on drying) may be acceptable.

The guideline provides PDE values and gives conversion tables to ppm, based on daily dose assumptions.

Analytical approaches and reporting

There are certain workflows that can be followed by analysts during testing of the solvent impurities. This is to make the standardization of the analytical methods.

1. Test only for solvents likely to be present.
   • Identify which solvents you used in the route. This is to save time and efforts of the analysts.
2. Preferred methods
   • Gas chromatography (GC) with headspace sampling is the usual choice. Hence, it it gives specificity and sensitivity to the analysis process.
3. Non-specific vs specific testing
   • If only Class 3 solvents are present, nonspecific methods such as loss on drying may be acceptable. Otherwise, use validated GC methods.
4. Method validation
   • Validate for linearity, accuracy, precision, and LOD (Limit of Detection)/LOQ (Limit of Quantification) as per ICH Q2 and Q3C recommendations.
5. Reporting expectations
   • Provide the list of solvents tested, methods used, results in ppm, and justification if any solvent exceeds limits. Regulators expect rationale and control strategy.

Control strategies in process development

1. Route selection
   • Choose reagents and solvents that are less toxic wherever possible. This eventually reduces regulatory burden.
2. Unit operations that remove solvents
   • Use distillation, solvent swaps, recrystallization, and drying under controlled conditions. Therefore, it is recommended by ICH to monitor residual levels after each step by using GC.
3. Solvent substitution and alternatives
   • Substitute Class 1/2 solvents with Class 3 alternatives where chemistry allows. Therefore, it is necessary to balance reaction performance and safety.
4. In-process monitoring
   • Implement in-process checks (e.g., headspace GC) for critical solvents that are hard to remove.
5. Specification setting
   • Set API and excipient specifications that reflect achievable and safe residual solvent levels. Use the PDE conversion to back-calculate ppm limits for your maximum daily dose.

Example:

If a synthetic route uses acetonitrile (a Class 2 solvent limited by PDE), you should quantify it in the API. If levels approach the PDE-converted limit, consider extra washing or solvent swap.

Critical discussion—gaps and practical issues

• PDE assumptions vary. PDEs reflect toxicology and daily dose assumptions. For high-dose products, the ppm limit will be lower. Therefore, ICH recommends calculating limits for the intended dose.
• New solvents enter practice. The ICH maintenance procedure allows adding new solvents and PDEs. Stay informed with ICH Q3C current updates and regulatory notices.
• Analytical interference and matrix effects. Complex API matrices can hide low-level solvents. Hence, the method development must account for co-eluting impurities.
• Harmonization vs regional practice. ICH aims to harmonize, but pharmacopeial chapters (e.g., USP <467>) (uspnf.com) and regional regulators add operational detail. Always cross-check USP and regional guidance during submission.

Practical checklist

• Map all solvents used in the route and downstream processes.
• Classify each solvent (Class 1/2/3) per ICH Q3C.
• Select analytical methods (headspace GC preferred). Always validate as per ICH Q2.
• Calculate concentration limits (ppm) from PDEs for your maximum daily dose.
• Document control measures and justify any deviations. Hence, it is mandatory to keep records for regulatory review.

References

1. ICH Q3C (R8)—Impurities: Guideline for Residual Solvents (Step 4). (ICH Database)
2. FDA—Q3C(R8) Guidance and FDA page on Q3C—background and PDE additions. (U.S. Food and Drug Administration)
3. EMA—ICH Q3C (R9) Guideline (Step 5) / PDF—EU view and the step-5 document. (European Medicines Agency (EMA))
4. USP General Chapter <467> Residual Solvents—pharmacopeial testing expectations and procedures. (uspnf.com)
5. ICH maintenance procedures & updates (FDA page)—how PDEs are revised and added. (U.S. Food and Drug Administration)

Pharmaceutical impurity solutions offered by SynThink Research Chemicals

We provide pharmaceutical impurity standards to support your method development and drug development projects. We are specialized in the synthesis of pharmacopeial and non-pharmacopeial API impurities. In addition to this, we also have capabilities for custom synthesis of API intermediates and building blocks that are required in the drug development process. We provide the services for the synthesis of small molecules ranging from milligram to gram scale. We deliver each product along with validated analytical data and a Certificate of Analysis. At Synthink we rigorously test the products at regular intervals to confirm their identity and quality. We have expertise in a wide range of products that are categorized as Impurities, Building Blocks, Intermediates, and Nitrosamines. Specifically, we provide various process-related and degradation impurities of sodium-glucose co-transporter 2 (SGLT2) inhibitors like Dapagliflozin, Empagliflozin and Canagliflozin. We are experts in the manufacturing of impurities of cholesterol-lowering drugs such as Atorvastatin, Rosuvastatin and Ezetimibe. Also, we offer impurities of the corticosteroid class of APIs, for example, Prednisone, Methylprednisolone, Dexamethasone, and Hydrocortisone.